nirsevimab Archives -

The clock has started ticking on the FDA’s review of Sanofi and AstraZeneca’s one-shot antibody to protect newborns

FDA starts review of Sanofi, AZ antibody for RSV prevention

https://pharmaphorum.com/news/fda-starts-review-of-sanofi-az-antibody-for-rsv-prevention/

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns

AZ, Sanofi get first green light for RSV prophylactic antibody

https://pharmaphorum.com/news/az-sanofi-get-first-green-light-for-rsv-prophylactic-antibody/

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of

CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevention

https://pharmaphorum.com/news/chmp-says-yes-to-sanofi-astrazeneca-antibody-for-rsv-prevention/

A pooled analysis of data for AstraZeneca and Sanofi’s respiratory syncytial virus (RSV) antibody nirsevimab has concluded that

AZ, Sanofi build case for one-shot RSV antibody

https://pharmaphorum.com/news/az-sanofi-build-case-for-one-shot-rsv-antibody/

Pfizer has been awarded breakthrough status from the FDA for its respiratory syncytial virus (RSV) vaccine in pregnant

After GSK stumble, Pfizer moves forward with RSV vaccine

https://pharmaphorum.com/news/after-gsk-stumble-pfizer-moves-forward-with-rsv-vaccine/

AstraZeneca and Sanofi now have the data they need in hand to press ahead with regulatory filings next

AZ, Sanofi prep filings for one-shot RSV antibody after trial win

https://pharmaphorum.com/news/az-sanofi-prep-filings-for-one-shot-rsv-antibody-after-trial-win/

nirsevimab